Styrelsen i Lipidor AB (”Lipidor” eller ”Bolaget”) har beslutat att genomföra en nyemission om högst 2 100 000 units (”Erbjudandet”) samt notera Bolagets aktier på Nasdaq First North Growth Market (”Nasdaq First North”). Teckningskursen per unit är 12 kr och varje unit består av två (2) aktier med teckningskurs om 6 kr per aktie samt […]
The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum of 2,100,000 units (the "Offer") and to list the Company's shares on the Nasdaq First North Growth Market ("Nasdaq First North"). The subscription price per unit is SEK 12 and each unit consists […]
Styrelsen i Lipidor AB (”Lipidor” eller ”Bolaget”) har beslutat att genomföra en nyemission om högst 2 100 000 units (”Erbjudandet”) samt notera Bolagets aktier på Nasdaq First North Growth Market (”Nasdaq First North”). Teckningskursen per unit är 12 kr och varje unit består av två (2) aktier med teckningskurs om 6 kr per aktie samt […]
(Stockholm 20 June, 2019) On 20 June2019, the Annual General Meeting (”AGM”) of Lipidor AB (publ) was held in Stockholm. Read below for a summary of the decisions made. Reporting The AGM approved the balance sheet and profit and loss statement for the financial year 2018. Dividend In accordance with the board's proposal, the AGM resolved […]
14 January 2019, Stockholm, Sweden. Lipidor AB, a Swedish drug development company with an ongoing fully financed Phase III study for a psoriasis medication, has successfully completed a private placement of 20 MSEK from Swedish and international investors. “We have received very positive feedback from both current and new investors on our outlooks as well […]
Stockholm, Sweden 4 October: Psoriasis is a chronic disease affecting 2-4% of the world’s population. A new anti-psoriasis spray now in a Phase III trial offers more comfort to patients, and improves dose control. The first patient has now entered the trial. Lipidor’s Calcipotriol Spray is being evaluated over 8 weeks of treatment in a […]
Ola Holmlund begins as Lipidor’s new CEO on September 1. With a powerful track record in Business Development and Strategic Sales, Holmlund says: “Lipidor is an exciting company with an exceptional technology, AKVANO, that I am confident could be the base for a wide range of new dermatological products worldwide. I’m delighted to be aboard.” […]
India’s CDSCO (Central Drugs Standard Control Organization) has approved Phase III Trials of a new topical anti-psoriatic spray developed by Swedish company Lipidor. The new spray is expected to overcome patient non-compliance, a major problem for traditional psoriasis creams and ointments. It is exceptionally fast-drying and easy to apply. Calcipotriol Spray consists of the generic […]
Lipidor AB, a pharmaceutical company developing innovative products based on its proprietary AKVANO® technology, announces today its plan to list the company during 2019. As part of the preparations Per Nilsson and Fredrik Sjövall have been elected new board members. ”Lipidor is in an exciting stage with our first candidate drug entering into a fully […]